METLIFE INVESTMENT MANAGEMENT, LLC

Thesis

MetLife Investment Management (MIM) is the institutional asset management arm of MetLife, Inc., a global financial services company. MIM operates as a diversified global asset manager offering a wide range of investment solutions across public and private markets, including corporate private placement debt, infrastructure debt, real estate equity, commercial mortgage loans, customized index strategies, structured finance, emerging market debt, and high yield. The firm's strategy involves building sustainable, tailored investment solutions to meet long-term investment objectives and risk-adjusted returns, emphasizing a client-centric approach. MIM's investment appetite includes buyout strategies, with a focus on Central/Eastern Europe and the biotech/life science sectors. They also actively invest in private equity and venture capital through their Next Gen Ventures program, targeting early to mid-stage companies (Series A-C) globally, with typical investment ranges of $3 million to $10 million. MIM's private equity portfolio is generally allocated approximately 70% to the US, 20% to Europe, and 10% to Asia. As of December 31, 2025, MetLife Investment Management reported $741.7 billion in total assets under management. The firm has closed several private equity funds, including MetLife Investment Private Equity Partners Fund III with $1.2 billion in commitments, MetLife Investment Private Equity Partners II with $1.2 billion in commitments, and MetLife Investment Private Equity Partners I with approximately $1.6 billion.

Related lists

• Seed-stage Healthcare investors
• Series A Healthcare investors
• Series B Healthcare investors